Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Osteoporosis International
Erschienen in: Osteoporosis International 4/2013

01.04.2013 | Original Article

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

verfasst von: O. Ström, B. Jönsson, J. A. Kanis

Erschienen in: Osteoporosis International | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Summary

The objective was to undertake a health economic analysis of denosumab for the treatment of osteoporosis in women from the UK, using the FRAX® tool. Denosumab was cost-effective in women with a risk of major osteoporotic fracture meeting or exceeding approximately 20 % who are unable to take, comply with or tolerate generic alendronate.

Introduction

Denosumab is a novel biologic agent developed for the treatment of osteoporosis, which has been shown to reduce the risk of fractures in a phase-III trial. The objective of the present study was to undertake a health economic analysis of denosumab in women from the UK. Ten-year probabilities of a major osteoporotic fracture at which denosumab is a cost-effective alternative to no treatment, generic alendronate, risedronate and strontium ranelate were estimated.

Methods

A previously published Markov model was adapted to incorporate fracture and mortality risk assessments based on absolute fracture probability, as estimated by FRAX®. The model included treatment persistence and residual effect after discontinuation.

Results

At a willingness-to-pay (WTP) of £30,000 per quality-adjusted life year and a 10-year fracture probability equivalent to a woman with a prior fragility fracture, denosumab was cost-effective compared to no treatment from the age of 70 years. At the same WTP, denosumab was—irrespective of age—cost-effective compared to no treatment at a major osteoporotic fracture probability of approximately 20 %. Denosumab was estimated to cost-effectively replace strontium, risedronate and generic alendronate at 10-year probabilities exceeding 11, 19 and 32 %, respectively.

Conclusion

FRAX® facilitates the estimation of cost-effectiveness-based intervention thresholds applicable to patients with different combinations of clinical risk factors, which more closely matches the situation in clinical practice. Denosumab is cost-effective in patients with major osteoporotic fracture probabilities meeting or exceeding approximately 20 % who are unable to take, comply with or tolerate generic alendronate.
Literatur
1.
Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK
2.
Kanis JA et al (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397PubMedCrossRef
3.
Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046PubMedCrossRef
4.
Fujiwara S et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19(4):429–435PubMedCrossRef
5.
Association Suisse contre l‘Osteoporose (2011) Osteoporose: Recommandations 2010. Bern
6.
Neuprez A et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64(12):612–619PubMed
7.
Grossman JM et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:15–26
8.
NOF (2008) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
9.
Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2012. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit. Stöd för styrning och ledning. 1-116. Publicerad
10.
Papaioannou A et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182(17):1864–1873PubMed
11.
U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356–364
12.
Kanis JA et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428PubMedCrossRef
13.
Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36(7):683–690, quiz 691PubMedCrossRef
14.
Compston J et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(2):105–108PubMedCrossRef
15.
National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
16.
National Institute for Health and Clinical Excellence (2010) Final appraisal determination 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London
17.
National Institute for Health and Clinical Excellence (2010) Final appraisal determination 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London
18.
19.
Kanis J et al (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos. doi:10.​1007/​s11657-010-0045-5
20.
Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408, Erratum published 2009 Osteoporos Int 20, 499–502PubMedCrossRef
21.
Borgstrom F et al (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(3):495–505PubMedCrossRef
22.
Borgstrom F et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21(2):339–349PubMedCrossRef
23.
Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765PubMedCrossRef
24.
Li L et al (2010) Non-persistence to anti-osteoporosis medications in the UK using the general practice research database (GPRD) Rheumatology 49 Supplement 1 (OP54)
25.
Landfeldt E et al (2012) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433–434PubMedCrossRef
26.
Jonsson B et al (2010) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982PubMedCrossRef
27.
Strom O et al (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23–34PubMedCrossRef
28.
29.
Strom O et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18(8):1047–1061PubMedCrossRef
30.
Kanis J et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29):1–146PubMed
31.
Stevenson M et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005 Jun;9(22):1–160PubMed
32.
Strom O et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47(2):430–437PubMedCrossRef
33.
Seeley DG et al (1991) Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115(11):837–842PubMed
34.
35.
Freemantle N et al (2011) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326PubMedCrossRef
36.
37.
Reginster JY et al (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45(6):1059–1064PubMedCrossRef
38.
Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243–248PubMedCrossRef
39.
de Lusignan S et al (2006) Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int 17(12):1808–1814PubMedCrossRef
40.
Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):iii–iv, ix-xi, 1–231PubMed
41.
42.
43.
Stevenson M, Davis S, Kanis J (2006) The hospitalization costs and outpatient costs of fragility fractures. Women's Health Med 4:149–151CrossRef
44.
Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRef
45.
Borgstrom F et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17(5):637–650PubMedCrossRef
46.
Ström O et al (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79(2):269–280PubMedCrossRef
47.
48.
Jonsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38PubMedCrossRef
49.
50.
Kanis JA et al (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112PubMedCrossRef
51.
Bliuc D et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301(5):513–521PubMedCrossRef
52.
Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473PubMedCrossRef
53.
Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781–1793PubMedCrossRef
54.
Kanis JA et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4–15PubMedCrossRef
55.
Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736–741CrossRef
56.
57.
Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide (NICE). The University of Sheffield, School of Health and Related Research, Sheffield
58.
Borgstrom F et al (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. PharmacoEconomics 22(17):1153–1165PubMedCrossRef
59.
Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX((R))-assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408PubMedCrossRef
60.
Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280(24):2077–2082PubMedCrossRef
61.
Scotland G et al (2011) Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. PharmacoEconomics 29(11):951–961PubMedCrossRef
62.
van Staa TP et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383–1389CrossRef
63.
Kanis JA et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16(7):737–742PubMedCrossRef
64.
Kanis JA et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411PubMedCrossRef
65.
Delmas PD et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522–532PubMedCrossRef
66.
Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739PubMedCrossRef
67.
Kanis JA et al (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int
68.
McCloskey EV et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20(5):811–817PubMedCrossRef
69.
Kanis JA et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049–1054PubMedCrossRef
70.
McCloskey EV, Johansson H, Oden A, (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. J Bone Miner Res. doi:10.​1002/​jbmr.​1606
Metadaten
Titel
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
verfasst von
O. Ström
B. Jönsson
J. A. Kanis
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 4/2013
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2115-6

Weitere Artikel der Ausgabe 4/2013

Osteoporosis International 4/2013 Zur Ausgabe

Original Article

Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study

Short Communication

Cold-activated brown adipose tissue is an independent predictor of higher bone mineral density in women

Original Article

Skeletal effects of zoledronic acid in an animal model of chronic kidney disease

Letter

Lactation, bone strength and reduced risk of bone fractures: reply to comment by Cure-Cure et al.

Original Article

Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome

Original Article

Hip fracture and other predictors of anti-osteoporosis drug use in Norway

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise